SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bart Hoenes who wrote (1094)5/23/1999 1:05:00 AM
From: Bernard Poulin   of 1185
 
Hopefully the stock continues to edge up on good volume as it's been doing.Then with the possibility of the ROCHE deal being signed within the next few weeks the stock should easily go past the $2.00 mark.After that sometimes in june i'm expecting well see another pharmaceutical giant get involved with their cough compound, followed by phase 1 trials that same month.Then we also have the phase 111 trials for their anasthetic which should also bring some sort of a distribution deal, i beleive that is slated for this fall.Something may also come out of the ASTRA association and their erection compound.All in all i see Golden Capitals price target of $3.75 as very attainable this year.And with any great sucess with their compounds NORTRAN could be well on their way to becoming another Biochem or QLT personaly i think they have a great shot at it! < any other opinions out their! >
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News